{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:29:00Z","timestamp":1762622940506,"version":"build-2065373602"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2805,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1997,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We tested the effects of clozapine, an \u201catypical\u201d neuroleptic with high affinity for the D4 (dopaminergic), and the 5\u2010HT1c and 5\u2010HT2 (serotonergic) receptor subtypes on locomotor activity in an animal model of Parkinson's disease showing a bimodal response curve to increasing doses of a D2 agonist. Sulpiride (D2 antagonist) and ritanserin (5\u2010HT1c and 5\u2010HT2 antagonist) were used for comparison. The D1 agonist SKF 38393 at a dose of 8 mg\/kg significantly reversed the akinesia induced by chronic reserpine treatment (1 mg\/kg for 5 days) and alpha\u2010methyl\u2010p\u2010tyrosine pretreatment (300 mg\/kg). In this model, the addition of a low dose of a D2 agonist, LY 171555 (quinpirole, 1 \u03bcg\/kg), inhibited the effects of SKF 38393, whereas the same drug at higher doses (5\u201350 \u03bcg\/kg) restored and potentiated the stimulatory response to D1 stimulation. Clozapine inhibited the inhibitory phase and potentiated the stimulatory phase of the curve. Sulpiride inhibited both phases of the dose\u2010response curve (inhibitory\/stimulatory), whereas ritanserin had no effect. We believe these results may reflect a disinhibition phenomenon possibly mediated by the blockade by clozapine of a subpopulation of inhibitory dopa\u2010mine (DA) receptors belonging to the D2 \u201cfamily\u201d.<\/jats:p>","DOI":"10.1002\/mds.870120205","type":"journal-article","created":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T20:21:54Z","timestamp":1117311714000},"page":"159-166","source":"Crossref","is-referenced-by-count":6,"title":["Mechanism of action of clozapine\u2010induced modification of motor behavior in an animal model of the \u201csuper\u2010off\u201d phenomenon"],"prefix":"10.1002","volume":"12","author":[{"given":"G.","family":"Dziewczapolski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. B.","family":"Menalled","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Savino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. J. E.","family":"Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gershanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.11.1024"},{"key":"e_1_2_1_3_2","first-page":"248","article-title":"Clinical profile of parkinsonian patients with super off phenomenon","volume":"44","author":"Gershanik O","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.10.1553"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1137-a"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90121-5"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.9.1219"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198904000-00001"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050310"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080317"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/S0007125000296840","article-title":"General pharmacology of clozapine","volume":"160","author":"Coward DM","year":"1992","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/350610a0"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90488-4"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)94100-C"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0922-4106(93)90126-T","article-title":"Clozapine and N\u2010 desmethylclozapine are potent 5\u2010HTIc receptor antagonist","volume":"245","author":"Kuoppam\u00e4ki M","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442554"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(92)90028-D"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000296876","article-title":"The importance of serotonin\u2010dopamine interactions in the action of clozapine","volume":"160","author":"Meltzer HY","year":"1992","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_19_2","first-page":"602","article-title":"Dopamine receptor pharmacology","volume":"6","author":"Seeman P","year":"1993","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0022-3565(25)20012-X","article-title":"Adaptative mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice","volume":"252","author":"Rubinstein M","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(74)90204-2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(75)90154-5"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(81)90022-8"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(83)90121-1"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(87)90110-9"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270613"},{"key":"e_1_2_1_27_2","first-page":"31","article-title":"Pharmacological properties of presynaptic dopamine receptor agonists","volume":"2","author":"Carlsson A","year":"1985","journal-title":"Psychopharmacology"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244979"},{"key":"e_1_2_1_29_2","first-page":"127","article-title":"The effect of a serotonin S2 antagonist, ritanserine, and an anticholinergic benztropine on haloperidol\u2010induced dystonia in nonhuman primates","volume":"30","author":"Casey DE","year":"1991","journal-title":"Am Coll Neuropsychopharmacol"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199212000-00004"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90665-S"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90565-L"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/1044-5765(92)90008-P"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90674-7"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01283032"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01277593"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90718-8"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0022-3565(25)12176-9","article-title":"Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents","volume":"275","author":"Sautel F","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0022-3565(25)12192-7","article-title":"Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907","volume":"275","author":"Pugsley TA","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)38500-9"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870120205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870120205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:28:07Z","timestamp":1760956087000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870120205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["10.1002\/mds.870120205"],"URL":"https:\/\/doi.org\/10.1002\/mds.870120205","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[1997,3]]}}}